Vanderbilt University has patented metabotropic glutamate receptor subtype 2 (mGluR2) negative allosteric modulators reported to be useful for the treatment of depression, anxiety, Alzheimer's disease, obsessive-compulsive and autism spectrum disorders.
Revelation Biosciences Inc. has entered into an exclusive worldwide license agreement with Vanderbilt University to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD) for treating or preventing infections.
Amytrx Therapeutics Inc., of Nashville, Tenn., founded in 2014 but coming out of stealth now, is developing a therapeutic for treating multiple inflammatory, autoimmune and metabolic diseases.
